Novo Nordisk CEO Puts Pricing On The Line
Executive Summary
Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.
You may also be interested in...
Novo Nordisk Warns About Insulin Pen Cartridge-Holder Problems
New insulin-cartridge holders are being sent to users worldwide after the use of cleaning chemicals was linked to cracked holders in specific batches of NovoPen Echo and NovoPen 5, and increased ADR risks.
Under Pressure: Sanofi Joins Call For Price Transparency
As Sanofi joined the ranks of pharma companies pledging to limit annual US price increases, the company also released average aggregate list and net prices in 2016, showing net prices declined 2.1%.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.